Pfizer Inc. (NYSE:PFE) Shares Acquired by MeadowBrook Investment Advisors LLC

MeadowBrook Investment Advisors LLC lifted its holdings in shares of Pfizer Inc. (NYSE:PFE) by 8.6% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 21,519 shares of the biopharmaceutical company’s stock after purchasing an additional 1,696 shares during the quarter. MeadowBrook Investment Advisors LLC’s holdings in Pfizer were worth $623,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Addison Advisors LLC boosted its holdings in shares of Pfizer by 394.2% during the third quarter. Addison Advisors LLC now owns 52,238 shares of the biopharmaceutical company’s stock worth $1,512,000 after purchasing an additional 41,668 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. raised its position in shares of Pfizer by 4.3% in the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 13,118,764 shares of the biopharmaceutical company’s stock worth $379,657,000 after buying an additional 544,418 shares during the period. LGT Group Foundation raised its position in shares of Pfizer by 2.5% in the 2nd quarter. LGT Group Foundation now owns 742,875 shares of the biopharmaceutical company’s stock worth $20,786,000 after buying an additional 18,274 shares during the period. Radnor Capital Management LLC purchased a new position in shares of Pfizer in the 3rd quarter worth $2,972,000. Finally, Kornitzer Capital Management Inc. KS raised its position in shares of Pfizer by 2.4% in the 3rd quarter. Kornitzer Capital Management Inc. KS now owns 1,168,315 shares of the biopharmaceutical company’s stock worth $33,811,000 after buying an additional 27,562 shares during the period. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Stock Down 0.8 %

Shares of NYSE PFE traded down $0.22 during midday trading on Thursday, reaching $26.50. 5,019,627 shares of the company’s stock were exchanged, compared to its average volume of 37,629,043. Pfizer Inc. has a 52-week low of $25.20 and a 52-week high of $31.54. The stock has a market capitalization of $150.18 billion, a PE ratio of 36.11, a price-to-earnings-growth ratio of 0.83 and a beta of 0.67. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The business’s fifty day moving average price is $28.76 and its two-hundred day moving average price is $28.67.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.64 by $0.42. The business had revenue of $17.70 billion for the quarter, compared to analyst estimates of $14.92 billion. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The company’s revenue for the quarter was up 31.2% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.17) earnings per share. Analysts forecast that Pfizer Inc. will post 2.96 EPS for the current year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be paid a $0.42 dividend. The ex-dividend date is Friday, November 8th. This represents a $1.68 dividend on an annualized basis and a yield of 6.34%. Pfizer’s dividend payout ratio (DPR) is 227.03%.

Insider Buying and Selling

In other news, Director Scott Gottlieb purchased 1,000 shares of the firm’s stock in a transaction that occurred on Wednesday, October 30th. The stock was acquired at an average cost of $28.24 per share, for a total transaction of $28,240.00. Following the completion of the purchase, the director now owns 10,000 shares of the company’s stock, valued at approximately $282,400. This trade represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.06% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on PFE. Daiwa America raised Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research report on Wednesday, August 7th. StockNews.com raised Pfizer from a “buy” rating to a “strong-buy” rating in a research report on Tuesday. Wells Fargo & Company raised their price objective on Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 31st. Citigroup began coverage on Pfizer in a research report on Friday, October 25th. They issued a “neutral” rating and a $30.00 price objective on the stock. Finally, Sanford C. Bernstein began coverage on Pfizer in a research report on Thursday, October 17th. They issued a “market perform” rating and a $32.00 price objective on the stock. Eight research analysts have rated the stock with a hold rating, five have given a buy rating and three have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $33.58.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.